Overview

Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008

Status:
Completed
Trial end date:
2020-06-05
Target enrollment:
Participant gender:
Summary
The objective of the study is to provide long term access to bosutinib treatment and assess long term safety, tolerability and duration of clinical benefit, without any formal hypothesis testing; therefore, there is no formal primary endpoint.
Phase:
N/A
Details
Lead Sponsor:
Pfizer